Printer Friendly

XOMA ANNOUNCES NEW E5 CLINICAL TRIAL

 BERKELEY, Calif., June 15 /PRNewswire/ -- XOMA Corp. (NASDAQ-NMS: XOMA) today announced the initiation of a new Phase III clinical trial of its E5 anti-endotoxin monoclonal antibody in the treatment of severe gram-negative sepsis, a disease that results from certain bacterial infections. As previously announced, the trial will be managed and co-funded by Pfizer Inc., XOMA's E5 marketing partner.
 The multicenter, randomized, double-blind, placebo-controlled trial will measure the effect of two daily doses of E5 or placebo on survival in patients with severe gram negative sepsis. Only patients with gram- negative infection (as documented by culture or selected Gram stains) and sepsis-related organ damage and/or shock will be eligible to participate.
 "By focusing on the types of patients who have benefited from E5 therapy in two previous randomized studies, the trial should demonstrate the efficacy of E5 in a prospectively identifiable patient population and address the cost-effectiveness concerns raised as a result of previous clinical trials of sepsis therapies," said XOMA Chairman and Chief Executive Officer John L. Castello.
 The trial design incorporates guidelines for the use of anti- endotoxin monoclonal antibodies established by the Infectious Diseases Society of America, and organization of prominent physicians that independently evaluated the published results of previous clinical trials of anti-endotoxin monoclonal antibodies including E5. The definitions utilized in this trial will be those recommended by a recent consensus of physicians from the American College of Chest Physicians and the Society of Critical Care Medicine.
 There can be no assurance that the new trail will yield data that will result in approval of E5 in the United States. Registration of E5 is being pursued separately in the countries of the European Community and in Japan.
 Over 200,000 cases of gram-negative sepsis occur each year in the United States, leading to approximately 70,000 deaths, according to data compiled by the federal Centers for Disease Control and Prevention. Gram-negative sepsis may occur following abdominal trauma, or as a complication of surgery, urinary tract infections or a weakened immune system. In cases of gram-negative sepsis, certain bacteria (known as gram-negative bacteria) release into the body a poison known as endotoxin. Although antibiotic therapy often is effective in killing the bacteria, such treatment is unable to prevent the bacteria from releasing endotoxin and triggering a cascade of physiological events that may lead to organ failure and death. E5 is designed to bind and inhibit the effects of endotoxin.
 XOMA is a biotechnology company engaged in the development of pharmaceutical products based on recombinant DNA and other technologies for the targeted treatment of infectious and immune system diseases and other serious disorders.
 -0- 6/15/93
 /CONTACTS: Carol DeGuzman of XOMA, 510-644-1170 or 510-644-1173 (before 10 a.m. EDT), or Mike Millican or Dan O'Connell of Robert Marston & Associates, 212-371-2200, for XOMA/
 (XOMA)


CO: XOMA Corp. ST: California IN: MTC SU:

LH-GT -- SF009 -- 1972 06/15/93 09:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:483
Previous Article:BAY AREA PRICES ROSE 0.1 PERCENT IN MAY -- UP 3.5 PERCENT OVER-THE-YEAR
Next Article:BEN FRANKLIN RETAIL STORES, INC. ISSUES $25 MILLION OF 7-1/2 PERCENT CONVERTIBLE SUBORDINATED NOTES
Topics:


Related Articles
FDA REVIEW OF XOMA'S E5(R) PRODUCT IS ACTIVE; COMPANY BELIEVES MARKET OVERREACTED
XOMA UPDATES FDA REVIEW STATUS OF E5
XOMA COMMENTS ON FDA REVIEW OF E5
XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
XOMA ANNOUNCES U.S. PATENT ON BPI PRODUCTION
MENDELL RESIGNS, CASTELLO ASSUMES CHAIRMAN ROLE AT XOMA
XOMA'S IMMUNOFUSION TECHNOLOGY HIGHLIGHTED AT MEETING
XOMA'S NEUPREX(TM) PRODUCT NEUTRALIZES ENDOTOXIN IN HUMANS
COURT DISMISSES SECURITIES CLAIMS AGAINST XOMA
Lexicon Genetics and XOMA Establish Collaboration for Antibody Drug Development and Commercialization.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters